Forodesine hydrochloride (BCX-1777) (Synonyms: BCX-1777 hydrochloride; Immucillin-H hydrochloride) |
| Catalog No.GC32708 |
Le chlorhydrate de forodésine (BCX-1777) (chlorhydrate de BCX-1777) est un inhibiteur de la purine nucléoside phosphorylase (PNP) très puissant et oralement actif avec des valeurs IC50 allant de 0,48 À 1,57 nM pour le PNP humain, souris, rat, singe et chien. Le chlorhydrate de forodésine (BCX-1777) est un puissant inhibiteur de la prolifération des lymphocytes humains. Le chlorhydrate de forodésine (BCX-1777) pourrait induire l'apoptose dans les cellules leucémiques en augmentant les niveaux de dGTP.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 284490-13-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Forodesine hydrochloride is a potent and oral purine nucleoside phosphorylase (PNP) inhibitor with IC50s ranging from 0.48 to 1.57 nM.
[1]. Homminga I, et al. In vitro efficacy of forodesine and nelarabine (ara-G) in pediatric leukemia. Blood. 2011 Aug 25;118(8):2184-90. [2]. Ogura M, et al. Phase I study of BCX1777 (forodesine) in patients with relapsed or refractory peripheral T/natural killer-cell malignancies. Cancer Sci. 2012 Jul;103(7):1290-5. [3]. Bieghs L, et al. The effects of forodesine in murine and human multiple myeloma cells. Adv Hematol. 2010;2010:131895. [4]. Yamauchi T, et al. A nelarabine-resistant T-lymphoblastic leukemia CCRF-CEM variant cell line is cross-resistant to the purine nucleoside phosphorylase inhibitor forodesine. Anticancer Res. 2014 Sep;34(9):4885-92.
Average Rating: 5 (Based on Reviews and 6 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *